/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers
Editor's note: Last October, in New York, Kiran Mazumdar-Shaw did what she does best—make the news. Talking at the UNAIDS Health Innovation Exchange held at the United Nations General Assembly, the founder of Biocon Ltd made an offer to make available human insulin at $0.10 per day to low- and middle-income countries, less than half the current prices. It was no mean offer, given that these countries accounted for 80% of the diabetes burden. Around the same time, in the Bengaluru headquarters of her company, managers were hard at work trying to find additional funds for several other things she had set in motion. As chairman and managing director, Mazumdar-Shaw was rapidly throwing more money into research, building new factories and hiring expatriate managers for her company. An idea to list a subsidiary overseas was on the table because she suspected that Indian investors wouldn’t value her firm appropriately. For those who have followed Mazumdar-Shaw over the last decade, the concurrent situation presents the dichotomy that has always surrounded her. Her business was the first to launch several copies of complex drugs …
While the filing for an IPO by its telecom and digital business was the highlight, Reliance laid out plans for its new energy and retail businesses, setting them up for eventual listings.
As India’s largest stock exchange heads to the public markets, it may need to rethink its excessive reliance on transaction revenue.
As growth in equities cools, asset managers are looking to embed themselves in payrolls, payments, and credit. This raises their influence, but also the stakes.
